Centre for Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ.
Centre for Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ
J Med Screen. 2014 Sep;21(3):113-9. doi: 10.1177/0969141314543128. Epub 2014 Jul 3.
Pregnancies with Edwards or Patau syndrome are often detected through screening for Down's syndrome. We aimed to evaluate the impact of screening for Down's syndrome on the prevalence of live births and antenatal diagnoses of Edwards and Patau syndrome.
England and Wales, 2005 to 2012.
Data from the National Down Syndrome Cytogenetic Register, which contains information on nearly all ante- or postnatally diagnosed cases of Edwards or Patau syndrome in which a karyotype was confirmed, were analysed.
From 2005 to 2012, 3,941 diagnoses of Edwards syndrome and 1,567 diagnoses of Patau syndrome were recorded (prevalence of 7.0 and 2.8 per 10,000 births respectively). Only 11% (95% confidence interval [CI]: 10-12) of diagnoses of Edwards syndrome and 13% (95% CI: 11-14) of Patau syndrome were live births, resulting in live birth prevalences of 0.8 (95% CI: 0.7-0.8) and 0.4 (95% CI: 0.3-0.4) per 10,000 live births respectively. About 90% of pregnancies with Edwards or Patau syndrome were diagnosed antenatally, and this proportion remained constant over time. The proportion of diagnoses detected before 15 weeks increased from 50% in 2005 to 53% in 2012 for Edwards syndrome, and from 41% in 2005 to 63% in 2012 for Patau syndrome.
Almost 700 women per year had a pregnancy with Edwards or Patau syndrome. Over 90% of these pregnancies were detected antenatally, with the increased use of first trimester screening for Down's syndrome resulting in the reduction in the mean gestational age at diagnosis of these syndromes.
爱德华氏综合征或帕陶氏综合征的妊娠通常通过唐氏综合征筛查来发现。我们旨在评估唐氏综合征筛查对活产率和爱德华氏综合征及帕陶氏综合征产前诊断的影响。
英格兰和威尔士,2005 年至 2012 年。
对国家唐氏综合征细胞遗传学登记处(该登记处包含经核型确认的几乎所有产前或产后诊断的爱德华氏综合征或帕陶氏综合征病例的信息)的数据进行分析。
2005 年至 2012 年,共记录了 3941 例爱德华氏综合征和 1567 例帕陶氏综合征的诊断(发病率分别为每 10000 例活产 7.0 和 2.8)。只有 11%(95%可信区间[CI]:10-12)的爱德华氏综合征诊断和 13%(95%CI:11-14)的帕陶氏综合征诊断为活产,导致活产率分别为每 10000 例活产 0.8(95%CI:0.7-0.8)和 0.4(95%CI:0.3-0.4)。约 90%的爱德华氏综合征或帕陶氏综合征妊娠在产前诊断,且这一比例随时间保持不变。2005 年至 2012 年,爱德华氏综合征诊断中 15 周前检出的比例从 50%增至 53%,帕陶氏综合征的比例从 41%增至 63%。
每年约有 700 名妇女怀有爱德华氏综合征或帕陶氏综合征。这些妊娠中,超过 90%在产前发现,唐氏综合征的第一孕期筛查的应用增加,导致这些综合征的诊断平均孕龄降低。